Literature DB >> 1090310

Selection of patients for bone marrow transplantation in severe aplastic anemia.

B M Camitta, J M Rappeport, R Parkman, D G Nathan.   

Abstract

Despite androgens and intensive supportive care, satisfactory survival in severe aplastic anemia remains at 20% or less. Histocompatible bone marrow transplantation can restore normal hematopoiesis in approximately 40% of similarly severe individuals. Delay of transplantation for 3 wk after diagnosis allows time for proper evaluation and for many spontaneous recoveries. Further delay increases risks of fatal complications and decreases chances for successful transplantation while the incidence of spontaneous remission declines. When available, early histocompatible bone marrow transplantation may be the treatment of choice for severe aplastic anemia.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090310

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Immunosuppressive therapy in aplastic anemia.

Authors:  Vineeta Gupta; Akash Kumar; Vijai Tilak; Isha Saini; Baldev Bhatia
Journal:  Indian J Pediatr       Date:  2012-01-25       Impact factor: 1.967

2.  CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL.

Authors:  Ute Fischer; Christian Ruckert; Bernd Hubner; Olaf Eckermann; Vera Binder; Tamam Bakchoul; Friedhelm R Schuster; Sylvia Merk; Hans-Ulrich Klein; Monika Führer; Martin Dugas; Arndt Borkhardt
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.

Authors:  Jeffrey J Pu; Rong Hu; Galina L Mukhina; Hetty E Carraway; Michael A McDevitt; Robert A Brodsky
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  Increased CD4+ and CD8+ effector memory T cells in patients with aplastic anemia.

Authors:  Xiaojing Hu; Yan Gu; Yingxue Wang; Yaqin Cong; Xun Qu; Conggao Xu
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

5.  Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?

Authors:  Jakob R Passweg; André Tichelli
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

6.  Epidemiological Features of Aplastic Anemia in Indian Children.

Authors:  Vineeta Gupta; Raghvendra Pratap; Akash Kumar; Isha Saini; Jyoti Shukla
Journal:  Indian J Pediatr       Date:  2013-10-10       Impact factor: 1.967

7.  Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia.

Authors:  Diego V Clé; Elias H Atta; Danielle S P Dias; Carlos B L Lima; Mariana Bonduel; Gabriela Sciuccati; Larissa A Medeiros; Michel M de Oliveira; Marco A Salvino; Marlene Garanito; Sara T Ollala Saad; Rodrigo T Calado; Phillip Scheinberg
Journal:  Haematologica       Date:  2015-04-10       Impact factor: 9.941

8.  The value of prognostic indices in aplastic anaemia.

Authors:  D T Sleijfer; N H Mulder; H O Nieweg
Journal:  Blut       Date:  1981-02

9.  Prognosis in acquired aplastic anemia. An approach in the selection of patients for allogeneic bone marrow transplantation.

Authors:  K P Hellriegel; M Züger; R Gross
Journal:  Blut       Date:  1977-01

10.  Next-generation-sequencing-spectratyping reveals public T-cell receptor repertoires in pediatric very severe aplastic anemia and identifies a β chain CDR3 sequence associated with hepatitis-induced pathogenesis.

Authors:  Pina F I Krell; Susanne Reuther; Ute Fischer; Thomas Keller; Stephan Weber; Michael Gombert; Friedhelm R Schuster; Corinna Asang; Polina Stepensky; Brigitte Strahm; Roland Meisel; Jens Stoye; Arndt Borkhardt
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.